Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Standard
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. / Symeonidis, Argiris; van Biezen, Anja; de Wreede, Liesbeth; Piciocchi, Alfonso; Finke, Juergen; Beelen, Dietrich; Bornhäuser, Martin; Cornelissen, Jan; Volin, Liisa; Mufti, Ghulam; Chalandon, Yves; Ganser, Arnold; Bruno, Benedetto; Niederwieser, Dietger; Kobbe, Guido; Schwerdtfeger, Rainer; de Witte, Theo; Robin, Marie; Kröger, Nicolaus; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
in: BRIT J HAEMATOL, Jahrgang 171, Nr. 2, 10.2015, S. 239-246.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
AU - Symeonidis, Argiris
AU - van Biezen, Anja
AU - de Wreede, Liesbeth
AU - Piciocchi, Alfonso
AU - Finke, Juergen
AU - Beelen, Dietrich
AU - Bornhäuser, Martin
AU - Cornelissen, Jan
AU - Volin, Liisa
AU - Mufti, Ghulam
AU - Chalandon, Yves
AU - Ganser, Arnold
AU - Bruno, Benedetto
AU - Niederwieser, Dietger
AU - Kobbe, Guido
AU - Schwerdtfeger, Rainer
AU - de Witte, Theo
AU - Robin, Marie
AU - Kröger, Nicolaus
AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N1 - © 2015 John Wiley & Sons Ltd.
PY - 2015/10
Y1 - 2015/10
N2 - The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.
AB - The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.
KW - Journal Article
U2 - 10.1111/bjh.13576
DO - 10.1111/bjh.13576
M3 - SCORING: Journal article
C2 - 26212516
VL - 171
SP - 239
EP - 246
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 2
ER -